Insys Therapeutics (INSY) Approves $50M Common Stock Buyback
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P, Nasdaq drop on semiconductor selloff as AI spending concerns mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Needham Starts NeoVolta (NEOV) at Buy
Insys Therapeutics Announces Stock Repurchase Program
November 5, 2015 6:52 AM ESTPHOENIX, Nov. 05, 2015 (GLOBE NEWSWIRE) -- Insys Therapeutics, Inc. (Nasdaq: INSY) (Insys or the Company) today announced that its Board of Directors has approved the repurchase of up to $50 million of the Company's common stock.
"The Board of Directors and management team believe that shares of Insys stock are an attractive investment opportunity, and we are pleased that Insys strong balance sheet and cash flow enable us to return value to shareholders through a stock repurchase program, said Dr. John Kapoor, Chairman, President and Chief Executive Officer. At the same time, we are continuing to... More
Insys Therapeutics Announces Stock Repurchase Program
November 5, 2015 6:52 AM ESTPHOENIX, Nov. 05, 2015 (GLOBE NEWSWIRE) -- Insys Therapeutics, Inc. (Nasdaq: INSY) (Insys or the Company) today announced that its Board of Directors has approved the repurchase of up to $50 million of the Company's common stock.
"The Board of Directors and management team believe that shares of Insys stock are an attractive investment opportunity, and we are pleased that Insys strong balance sheet and cash flow enable us to return value to shareholders through a stock repurchase program, said Dr. John Kapoor, Chairman, President and Chief Executive Officer. At the same time, we are continuing to... More
Insys Therapeutics Announces Senior Management Changes and Appointments
November 5, 2015 6:51 AM ESTMichael Babich Departs as Insys President and CEO
Dr. John N. Kapoor Appointed President and CEO
Daniel Brennan Appointed Executive Vice President and Chief Operating Officer
PHOENIX, Nov. 05, 2015 (GLOBE NEWSWIRE) -- Insys Therapeutics, Inc. (NASDAQ: INSY) ("Insys" or "the Company") today announced that Michael L. Babich has stepped down as President and Chief Executive Officer of Insys. The Board of Directors has appointed Dr. John N. Kapoor as President and Chief Executive Officer effective November 4, 2015. Dr. Kapoor will... More
